Abstract 5415: Targeted nanoparticle based therapy for the treatment of glioblastoma multiforme: Unprecedented anti-cancer activity in highly drug resistant/refractory mouse models of glioblastoma with novel apoptotic nanoparticles which hone to a cell-surface protein f

Glioblastoma multiforme (GBM) or “glioblastoma,” is the most common and aggressive malignant primary brain tumor in humans. An effective treatment that increases patient survival would represent a significant advance in the field, and provide a desperately needed new therapy for this deadly disease. Herein we disclose the identification of the target of the tumor homing peptide which, when conjugated to ‘nanoworms’, deliver and carry the pro-apoptotic nanoparticle system selectively to the tumor target tissue. This nanosystem has shown unprecedented anti-cancer activity in highly drug resistant/refractory mouse models of glioblastoma, which closely mimic the human disease and thus provide an exciting new opportunity for the treatment of GBM. Plans for further development of this Nanosystem will also be discussed. Citation Format: Sarah Hudson, Lilach Agemy, Venkata Ramana Kotamraju, Shweta Sharma, Erkki Ruoslahti, Florence Brunel, Ann MacLaren, John Muraski, Deborah Slee. Targeted nanoparticle based therapy for the treatment of glioblastoma multiforme: Unprecedented anti-cancer activity in highly drug resistant/refractory mouse models of glioblastoma with novel apoptotic nanoparticles which hone to a cell-surface protein f [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5415. doi:10.1158/1538-7445.AM2014-5415